PRESS RELEASE published on 05/03/2023 at 12:30, 3 years 5 months ago Empower Clinics Advances Research and Clinical Trials Division with The Signing of Another Experienced Principal Investigator
PRESS RELEASE published on 04/25/2023 at 12:30, 3 years 5 months ago Empower Clinics Accelerates Growth of Research and Clinical Trials Division with Signing of Two Additional Principal Investigators at First Site in Dallas, Texas
PRESS RELEASE published on 04/20/2023 at 12:30, 3 years 5 months ago Empower Clinics Announces Official Launch of Mobile Technology & Communications Platform, PulseIR Powered by Fobi
PRESS RELEASE published on 04/17/2023 at 12:30, 3 years 6 months ago Empower Clinics Signs Agreement To Conduct Research and Clinical Trials with Dallas, TX Based Medical Center - And Major Milestone With Signing Of Research Services Agreement With First Principal Investigator
PRESS RELEASE published on 03/21/2023 at 11:00, 3 years 6 months ago Empower Clinics Announces Exploration of Strategic Alternatives
PRESS RELEASE published on 03/20/2023 at 08:00, 3 years 6 months ago Empower Clinics Cancels Previously Announced Private Placement
PRESS RELEASE published on 03/07/2023 at 13:00, 3 years 7 months ago Empower Clinics Advances Partnership to Launch US Clinical Trial Management Services with Formation of Delaware Based Company and Identification of Principal Investigators
PRESS RELEASE published on 03/01/2023 at 01:20, 3 years 7 months ago CORRECTION: Empower Clinics Reports Q4 2022 Results
PRESS RELEASE published on 02/28/2023 at 23:00, 3 years 7 months ago Empower Clinics Reports Q4 2022 Results
PRESS RELEASE published on 02/27/2023 at 23:40, 3 years 7 months ago CORRECTION: Empower Clinics Announces FOBI Partnership To Elevate Investor Relations With Digital, Mobile and Personalized Engagement
Published on 10/19/2026 at 23:20, 38 minutes ago CoTec Holdings Corp. Announces Investor Awareness Agreements
Published on 10/19/2026 at 23:00, 58 minutes ago Eskay Mining Corp. Announces Results of Annual Meeting
Published on 10/19/2026 at 22:50, 1 hour 8 minutes ago Bluesky Digital Announces Termination of ChessGold Inc. Transaction and Management and Director Changes
Published on 10/19/2026 at 22:01, 1 hour 57 minutes ago Unusual Machines Completes Acquisition of Upgrade Energy, Expanding U.S. Drone Battery Manufacturing
Published on 10/19/2026 at 22:16, 1 hour 42 minutes ago EQS-Adhoc: Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027
Published on 10/19/2026 at 21:22, 2 hours 36 minutes ago EQS-Adhoc: Cantourage Group SE: Supervisory Board Resolves to Transition to IFRS Following First-Time Requirement to Prepare Consolidated Financial Statements
Published on 10/19/2026 at 19:00, 4 hours 58 minutes ago PATRIMOINE ET COMMERCE : Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 12/10/2026 au 16/10/2026
Published on 10/19/2026 at 18:05, 5 hours 53 minutes ago Cognizant and Google Cloud Expand Alliance to Accelerate Agentic Enterprise Transformation
Published on 10/19/2026 at 17:45, 6 hours 13 minutes ago VALBIOTIS SA: Valbiotis receives double “Best Pharma Product 2027” award for its ValbiotisPRO® Cholestérol and ValbiotisPRO® Santé Métabolique solutions
Published on 10/19/2026 at 19:00, 4 hours 58 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 : Compte rendu et résultat des votes - Évolution de la gouvernance
Published on 10/19/2026 at 18:40, 5 hours 18 minutes ago Reporting on share buyback transactions carried out between October 12 and October 13, 2026
Published on 10/19/2026 at 18:40, 5 hours 18 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain les 12 et 13 octobre 2026
Published on 10/19/2026 at 18:00, 5 hours 58 minutes ago WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
Published on 10/19/2026 at 18:00, 5 hours 58 minutes ago L’OMS accorde une autorisation d’utilisation d’urgence au test BIOFIRE® Global Fever Special Pathogens, élargissant l’accès au diagnostic différentiel face à l’épidémie d’Ebola
